Search results (1331)
« Back to PublicationsWhat do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options.
Duffles Amarante G. et al, (2020), Br J Haematol, 188, 831 - 837
Pharmacodynamic effect of tebentafusp (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma
Middleton MR. et al, (2020), JOURNAL OF TRANSLATIONAL MEDICINE, 18
Relationship between clinical efficacy and AEs of tebentafusp, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma
Middleton MR. et al, (2020), JOURNAL OF TRANSLATIONAL MEDICINE, 18
A Phase 1 Trial of RP1: A New Oncolytic Virus Alone and in Combination with Nivolumab
Middleton M. et al, (2020), ANNALS OF SURGICAL ONCOLOGY, 27, S132 - S132
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
Gupta A. et al, (2020), Br J Cancer, 122, 506 - 516
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 159 - 177
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019.
Garbe C. et al, (2020), Eur J Cancer, 126, 141 - 158
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma.
Fairfax BP. et al, (2020), Nat Med, 26, 193 - 199
The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.
Jeanpierre S. et al, (2020), Haematologica, 106, 111 - 122
An ontogenetic switch drives the positive and negative selection of B cells
CORNALL R. et al, (2020), PNAS
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
Blagden SP. et al, (2020), British Journal of Cancer
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
Peach H. et al, (2020), J Plast Reconstr Aesthet Surg, 73, 36 - 42
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Goswami P. et al, (2020), Front Pharmacol, 11
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Goswami P. et al, (2020), Front Pharmacol, 11
Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?
Cheung VTF. et al, (2020), JOURNAL OF CROHNS & COLITIS, 14, S286 - S288
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Goswami P. et al, (2020), Ther Adv Hematol, 11
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Goswami P. et al, (2020), Front Pharmacol, 11
Technological advances and computational approaches for alternative splicing analysis in single cells.
Wen WX. et al, (2020), Comput Struct Biotechnol J, 18, 332 - 343